PharmTech Drug Digest 11.20
|Articles|April 21, 2011

USP Drug Quality Pilot Program Underway in Sub-Saharan Africa

On Apr. 18, 2011, scientists from the national laboratories of five African nations gathered in Accra, Ghana, to take part in a week of technical training put on by the US Pharmacopeia (USP) that will teach them how to detect substandard and counterfeit medicines.

On Apr. 18, 2011, scientists from the national laboratories of five African nations gathered in Accra, Ghana, to take part in a week of technical training put on by the US Pharmacopeia (USP) that will teach them how to detect substandard and counterfeit medicines.

USP is providing participants from Ethiopia, Ghana, Kenya, Senegal, and Sierra Leone with pharmaceutical reference standards, documentary standards, and technical writing training in an effort to improve help the quality of those countries’ medicines.  The instruction is a part of a pilot Technical Assistance Program (TAP) that was introduced earlier this year and funded by USP.

USP developed TAP based on feedback from participants about topics they wanted to see addressed most.  National laboratories in these countries often have to rely on unreliable or outdated standards to analyze medicines. The laboratories also may not be equipped to offer analysts the scientific training needed to appropriately analyze medicines.

As a result, accurate outcomes may not be obtained when questionable substances are tested. “Having a team of scientists trained in essential analytical techniques is a fundamental aspect of a well-functioning regulatory system that protects domestic drug supply,” said Patrick Lukulay, director of the PQM program in a USP press release.

The objective of the training is to improve the technical competence of the scientists and familiarize participants with information contained in the USP-NF, including how to use the information, according to the USP release.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.